anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
Myovant Sciences · conference-presentation

Myovant Sciences | Results Presentation Deck | 34 slides

34 pages · 3 arc beats · 2 loops

Conference-Presentation Download JSON
Unlock

Myovant Sciences | Results Presentation Deck | 34 slides

Myovant Sciences · 2022-08
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
— No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.
—

Deck intelligence map

3
coverage by narrative range · generated from this deck JSON
Narrative range 3 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem 1 slides 100% 1/1 slides 100% 1/1 slides · 8 hits
— 0/1 slides
— 0/1 slides
— 0/1 slides
100% 1/1 slides 100% 1/1 slides Solution 1 slides 100% 1/1 slides 100% 1/1 slides · 4 hits
— 0/1 slides
— 0/1 slides
— 0/1 slides
100% 1/1 slides
— 0/1 slides
Market Size 1 slides 100% 1/1 slides 100% 1/1 slides · 7 hits
— 0/1 slides
— 0/1 slides
— 0/1 slides
100% 1/1 slides
— 0/1 slides

Slide inventory

34
every slide · same image gating as the playbook
01
Slide 1
front_matter
Open slide detail
02
transition
Open slide detail
03
other
Open slide detail
04
front_matter
Open slide detail
05
The slide emphasizes the 'first and only' status of the drug for these two conditions.establish_context
Open slide detail
06
Uses a bar chart visualization to represent patient population segments.size_opportunity
Open slide detailLoop · Cost Of Inaction
07
The slide uses icons to represent four distinct pillars of growth: product profile, market synergy, financial milestone, and strategic pipeline expansion.summarize
Open slide detailLoop · Cost Of Inaction
08
transition
Open slide detailLoop · Cost Of Inaction
09
Includes citations for data points.diagnose_problem
Open slide detailBeat · ProblemLoop · Cost Of Inaction
10
Includes a disclaimer about the 24-month usage limit due to bone loss risk.other
Open slide detailLoop · Cost Of Inaction
11
The slide uses a timeline-based process diagram to illustrate the clinical trial structure.present_framework
Open slide detailLoop · Cost Of Inaction
12
Clinical trial data presentation with p-values and sample sizes.summarize
Open slide detailLoop · Cost Of Inaction
13
The slide includes a footnote defining the response rate criteria and a disclaimer that it is not for promotion.analyze_data
Open slide detailLoop · Cost Of Inaction
14
The chart highlights a 74.1% mean reduction in NRS score for MYFEMBREE vs 26.4% for placebo at week 24.analyze_data
Open slide detailLoop · Cost Of Inaction
15
The slide highlights a 49.7% reduction in NMPP NRS score at week 24 for the pooled MYFEMBREE group compared to 36.0% for placebo.analyze_data
Open slide detailLoop · Cost Of Inaction
16
The chart highlights a 57.9% mean reduction in pain domain score for the pooled MYFEMBREE group versus 32.6% for placebo at week 24.analyze_data
Open slide detailLoop · Cost Of Inaction
17
The chart shows a greater reduction in pain scores for the treatment group compared to placebo, with p < 0.05 significance indicated for both trials.analyze_data
Open slide detailLoop · Before After
18
Includes clinical trial data for opioid rescue usage at baseline vs month 6.analyze_data
Open slide detail
19
Standard pharmaceutical safety disclosure slide.other
Open slide detail
20
Clinical safety data table for MYFEMBREE.analyze_data
Open slide detail
21
Data from SPIRIT 1 and 2 studies only.analyze_data
Open slide detail
22
The chart shows a decrease in BMD for the treatment group compared to a slight increase for the placebo group.analyze_data
Open slide detail
23
The slide compares a control/observational group against a treatment group (SPIRIT study) to show BMD changes.analyze_data
Open slide detail
24
The table presents efficacy percentages for MYFEMBREE vs placebo (in parentheses) for three pain metrics, plus safety data.analyze_data
Open slide detailBeat · Solution
25
transition
Open slide detail
26
The slide uses a Venn diagram to illustrate the intersection of Efficacy, Safety & Tolerability, and Clear, Simple Dosing.present_solution
Open slide detail
27
present_solution
Open slide detail
28
Uses a Venn diagram to illustrate target overlap.establish_context
Open slide detail
29
The slide uses a donut chart to visualize the split between initial coverage and ongoing payer discussions.analyze_data
Open slide detailBeat · Market Size
30
The slide uses a hub-and-spoke diagram centered on a patient photo to illustrate support services.present_solution
Open slide detail
31
The slide uses a visual comparison matrix to highlight the 'one pill, once-a-day' value proposition.compare_peers
Open slide detail
32
Uses a split-screen layout to contrast 'Today' vs 'Tomorrow' strategic focus areas.summarize
Open slide detail
33
Features four executives with headshots in hexagonal frames.introduce_nominees
Open slide detail
34
front_matter
Open slide detail